Study of talabostat [PT 100] and rituximab in advanced chronic lymphocytic leukemia (CLL)
Phase of Trial: Phase II
Latest Information Update: 30 Mar 2015
At a glance
- Drugs Rituximab (Primary) ; Talabostat (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Point Therapeutics
- 24 Mar 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 08 Sep 2005 New trial record.